68
Participants
Start Date
January 2, 2022
Primary Completion Date
June 8, 2022
Study Completion Date
June 8, 2022
Group- A (100% weight-bearing; n=14), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.
"Moderate-intensity aerobic exercise training on the antigravity treadmill (100% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)."
Group- B (70% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.
"Moderate-intensity aerobic exercise training on the antigravity treadmill (70% weight-bearing) plus medications plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)"
Group- C (50% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.
"Moderate-intensity aerobic exercise training on the antigravity treadmill (50% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)"
Group- D (30% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.
"Moderate-intensity aerobic exercise training on the antigravity treadmill (30% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)."
Group- E; Control group
"Control: No aerobic exercise training on the antigravity treadmill, but only medications (Biguanide alone or Sulfonylureas plus Biguanide combination) throughout the study."
Umm Al-Qura University, Jeddah
Umm Al-Qura University
OTHER